Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.79 |
| ▸ | CA4 | P22748 | 3/20 | 0.79 |
| ▸ | CA1 | P00915 | 3/20 | 0.72 |
| ▸ | CA12 | O43570 | 2/20 | 0.72 |
| ▸ | CA6 | P23280 | 2/20 | 0.72 |
| ▸ | CA5A | P35218 | 2/20 | 0.72 |
| ▸ | CA7 | P43166 | 2/20 | 0.72 |
| ▸ | CA9 | Q16790 | 2/20 | 0.72 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.72 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576264 | 1.00 | CA2 (0.79) | CA2CA4CA1CA12CA6 | |
| SCHEMBL2631258 | 1.00 | CA2 (0.79) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7847722 | 0.94 | CA2 (0.69) | CA2CA4CA1CA12CA6 | |
| SCHEMBL7517336 | 0.94 | CA2 (0.69) | CA2CA4CA1CA12CA6 | |
| SCHEMBL8950315 | 0.90 | CA2 (0.64) | CA2CA4CA1CA12CA6 | |
| N-Desethyl Brinzolamide SCHEMBL2631262 | 0.88 | CA2 (1.00) | CA2CA4CA1CA12CA6 | |
| SCHEMBL9600441 | 0.87 | CA2 (0.70) | CA2CA4CA1CA12CA6 | |
| SCHEMBL9595980 | 0.86 | CA2 (0.60) | CA2CA4CA1CA12CA6 | |
| N-Desethyl Brinzolamide SCHEMBL31252384 | 0.86 | CA2 (0.90) | CA2CA4CA1CA12CA6 | |
| SCHEMBL31252424 | 0.85 | CA2 (0.82) | CA2CA4CA1CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145836-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | ICROM SPA (IT) | 2021-05-20 | — | — | US | disclosed |
| US-20210145836-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | ICROM SPA (IT) | 2021-05-20 | — | — | US | disclosed |
| US-10953115-B2 | Production of sterile active pharmaceutical ingredients | Icrom S.R.L. (IT) | 2021-03-23 | — | — | US | disclosed |
| US-10953115-B2 | Production of sterile active pharmaceutical ingredients | Icrom S.R.L. (IT) | 2021-03-23 | — | — | US | disclosed |
| EP-2846845-B1 | PRODUCTION OF STERILE PHARMACEUTICAL BRINZOLAMIDE | ICROM SPA (IT) | 2017-03-01 | — | — | EP | disclosed |
| US-20150141412-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | ICROM SPA (IT) | 2015-05-21 | — | — | US | disclosed |
| CN-104487099-A | Production of sterile active pharmaceutical ingredients | ICROM SPA | 2015-04-01 | — | — | CN | disclosed |
| US-20100317655-A1 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317655-A1 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | USV LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| EP-2079749-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (R)-(+)-4-(ETHYIAMINO)-3,4-DIHYDRO-2-(3- METHOXYPROPYL)-2H-THIENO[3,2-E]-L,2-THIAZINE-6-SULFONAMIDE-L,L-DIOXIDE | USV LIMITED (IN) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008062463-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (R)-(+)-4-(ETHYIAMINO)-3,4-DIHYDRO-2-(3- METHOXYPROPYL)-2H-THIENO[3,2-E]-L,2-THIAZINE-6-SULFONAMIDE-L,L-DIOXIDE | USV LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| US-5378703-A | FOR CONTROLLING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| US-5240923-A | Treating glaucoma | ALCON LABORATORIES, INC. (US) | 1993-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141412-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | AP3S1, ALPG, LSS | CA2 2669/4885CA4 2368/4885CA1 2835/4885 |
| US-20100009977-A1 | Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. | SULT1E1, SULT1A1, SULT2A1 | CA2 1631/4885CA4 709/4885CA1 2298/4885 |
| US-20100317655-A1 | SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA9, CA1 | CA2 1/4885CA4 5/4885CA1 3/4885 |
| US-20210145836-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | AP3S1, ALPG, LSS | CA2 2669/4885CA4 2368/4885CA1 2835/4885 |
| US-10953115-B2 | Production of sterile active pharmaceutical ingredients | AP3S1, ALPG, LSS | CA2 2669/4885CA4 2368/4885CA1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.